


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1.(currently amended) A method for treating ~~ameliorating or substantially preventing~~ an infectious disease, autoimmune disease or allergic condition in a subject comprising contacting the subject with an effective amount of one or more compounds having the formula:



(I)

and pharmaceutically acceptable salts there of, wherein X is a member selected from the group consisting of -O- and -NH-;

Y is a member selected from the group consisting of -O- and -S-;

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each members independently selected from the group consisting of (C<sub>2</sub>-C<sub>20</sub>)acyl;

$R^4$  is a member selected from the group consisting of -H and  $-\text{PO}_3\text{R}^7\text{R}^8$ , wherein  $R^7$  and  $R^8$  are each members independently selected from the group consisting of -H and (C<sub>1</sub>-C<sub>4</sub>)aliphatic groups;

$R^5$  is a member selected from the group consisting of -H, -CH<sub>3</sub> and  $-\text{PO}_3\text{R}^9\text{R}^{10}$ , wherein  $R^9$  and  $R^{10}$  are each members independently selected from the group consisting of -H and (C<sub>1</sub>-C<sub>4</sub>)aliphatic groups;

$R^6$  is selected from H, OH, (C<sub>1</sub>-C<sub>4</sub>)oxyaliphatic groups,  $-\text{PO}_3\text{R}^{11}\text{R}^{12}$ ,  $-\text{OPO}_3\text{R}^{11}\text{R}^{12}$ ,  $-\text{SO}_3\text{R}^{11}$ ,  $-\text{OSO}_3\text{R}^{11}$ ,  $-\text{NR}^{11}\text{R}^{12}$ ,  $-\text{SR}^{11}$ , -CN, -NO<sub>2</sub>, -CHO,  $-\text{CO}_2\text{R}^{11}$ , and  $-\text{CONR}^{11}\text{R}^{12}$ , wherein  $R^{11}$  and  $R^{12}$  are each independently selected from H and (C<sub>1</sub>-C<sub>4</sub>)aliphatic groups, with the provisos that one of  $R^4$  and  $R^5$  is a phosphorus-containing group and that when  $R^4$  is  $-\text{PO}_3\text{R}^7\text{R}^8$ ,  $R^5$  is other than  $-\text{PO}_3\text{R}^9\text{R}^{10}$ ;

wherein “\*<sup>1</sup>”, “\*<sup>2</sup>”, “\*<sup>3</sup>” and “\*\*\*” represent chiral centers;

wherein  $n$ ,  $m$ ,  $p$  and  $q$  are each independently an integer from 0 to 6, with the proviso that the sum of  $p$  and  $m$  is from 0 to 6.

2.(original) The method of claim 1, wherein X and Y are -O-,  $R^4$  is  $\text{PO}_3\text{R}^7\text{R}^8$ ,  $R^5$  and  $R^6$  are H, and  $n$ ,  $m$ ,  $p$ , and  $q$  are integers from 0 to 3.

3. (original) The method of claim 2, wherein  $R^7$  and  $R^8$  are -H.

4. (original) The method of claim 2, wherein  $n$ ,  $m$ ,  $p$ , and  $q$  are from 0 to 2.

5. (original) The method of claim 2, wherein  $n$  is 1,  $m$  is 2, and  $p$  and  $q$  are 0.

6. (original) The method of claim 1 wherein  $R_1$ ,  $R_2$  and  $R_3$  are each C<sub>6</sub>-C<sub>14</sub> acyl.

7. (original) The method of claim 1 wherein  $R_1$ ,  $R_2$ ; and  $R_3$  are each C<sub>6</sub>-C<sub>12</sub> acyl.

8. (original) The method of claim 5 wherein  $R_1$ ,  $R_2$ , and  $R_3$  are each decanoyl residues.

9. (original) The method of claim 5 wherein  $R_1$ ,  $R_2$ , and  $R_3$  are each dodecanoyl residues.

10. (original) The method of claim 5, wherein  $R_1$ ,  $R_2$ , and  $R_3$  are each tetradecanoyl residues.

11. (original) The method of claim 5, wherein \*<sup>1</sup>, \*<sup>2</sup>, and \*<sup>3</sup> are in the *R* configuration.
12. (original) The method of claim 5, wherein Y is in the equatorial position.
13. (original) The method of claim 5, wherein \*\* is in the *S* configuration.
14. (original) The method of claim 5, wherein \*<sup>1</sup>, \*<sup>2</sup>, and \*<sup>3</sup> are in the *R* configuration, wherein Y is in the equatorial position, and wherein \*\* is in the *S* configuration.
15. (original) The method of claim 1, wherein the infectious disease is caused by a bacteria, a virus, a parasite, or a fungus.
16. (original) The method of claim 15, wherein said bacteria is a gram negative bacteria, or a gram positive bacteria.
17. (original) The method of claim 15, wherein the infectious disease is caused by a bacteria selected from the group consisting of *Pseudomonas*, *Escherichia*, *Klebsiella*, *Enterobacter*, *Proteus*, *Serratia*, *Candida*, *Bacillus*, and *Staphylococcus*.
18. (original) The method of claim 17, wherein the infectious disease is pneumonia.
19. (original) The method of claim 18, wherein said pneumonia is nosocomial pneumonia.
20. (original) The method of claim 19, wherein said pneumonia is in an HIV-positive patient.
21. (original) The method of claim 1, wherein said infectious disease is a chronic infection.
22. (original) The method of claim 21, wherein said chronic infection comprises chronic hepatitis, human papillomavirus, oral or vaginal candidiasis, periodontal disease or chronic rhinosinusitis due to fungal colonization.

23. (withdrawn) The method of claim 1, wherein said allergic condition is selected from the group consisting of asthma, atopic dermatitis, seasonal allergic disorder and chronic rhinosinusitis.

24.(withdrawn) The method of claim 1, wherein said autoimmune disease is selected from the group consisting of inflammatory bowel disease, rheumatoid arthritis, chronic arthritis, multiple sclerosis and psoriasis.

25. (original) The method of claim 1, wherein said compound is administered to said animal by a route selected from the group consisting of parenteral, oral, intravenous, infusion, intranasal, inhalation, transdermal and transmucosal.

26-60. (canceled)

61 ~~62~~.(currently amended) A method for treating ameliorating or substantially preventing an infectious disease, autoimmune disease or allergic condition in a subject comprising contacting the subject with an effective amount of a cyclic AGP.

62 ~~63~~.(currently amended) The method of claim 62 wherein said cyclic AGP is *N*-[(*R*)-3-dodecanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinylmethyl 2-deoxy-4-*O*-phosphono-2-[(*R*)-3-dodecanoyloxy-tetradecanoylamino]-3-*O*-[(*R*)-3-dodecanoyloxytetradecanoyl]- β-D-glucopyranoside or a ~~pharmaceutically~~ pharmaceutically acceptable salt thereof.

63 ~~64~~.(currently amended) The method of claim 62 wherein said cyclic AGP is *N*-[(*R*)-3-decanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinylmethyl 2-deoxy-4-*O*-phosphono-2-[(*R*)-3-decanoyloxytetradecanoylamino]-3-*O*-[(*R*)-3-decanoyloxytetradecanoyl]- β-D-glucopyranoside or a pharmaceutically acceptable salt thereof.